fbpx

Stay Informed. Stay Competitive. Get Free Email Updates Dow 30 & Emerging Growth

Stay Informed. Stay Competitive.

Get Free Updates

Dow 30 & Emerging Growth

Debt-Ceiling Extension & Energy Fuels Stock Market Bounce To Produce Weekly Gains – $CCXI $INVO $NFLX $TSLA $XLE Rise!

By John F. Heerdink, Jr.
Debt-Ceiling Extension & Energy Fuels
“The deal machinations many companies put themselves through, while certainly a bonanza for investment bankers, can confound the typical investor.” – Whitney Tilson, American Businessman, Born 1966


Happy Weekend All!

I hope that you all had a wonderful week and that the rebound in the markets helped to enrich your investment accounts to heights that you never imagined. If we are dreaming, then maybe to levels similar to where the Blue Angels are achieving as they fly over my head this weekend during the annual Fleet Week Celebration in San Francisco. Please see the picture below that I snapped from my back deck on Friday! They are truly amazing to see & hear this close!

As for as the stock market, it rebounded after last week’s selloff. However the rebound, really did not begin until later in the week, when the Senate approved a bill on Thursday that is extending the debt ceiling by $480B & through Dec. 3rd.  Even with that decision, volatility seems to be here to stay as we are still living with the fact that energy prices, persistent, albeit transient, supply-chain disruptions, and labor-market shortages are expected to be with us, at least for the immediate future. 

At the end of the week, the markets closed as follows: The S&P 500 closed at 4,391.34 (+.8%) & is up 16.9% YTD, the Dow 30 closed at 34,746.25 (+1.2%) & is up 13.5% YTD, & the Nasdaq closed at 14,579.54 (+.8%) and is up 13.1% YTD. 8 of the 11 sectors closed in the green as the energy sector popped 5% as oil prices surged to close at $79.49 up 4.8% weekly (+63.8% YTD) (a 7-year-high) as OPEC+ continues to manipulate prices via their restrictive and coordinated agreement. Natural gas also rose for a moment this week to 2008 levels and have doubled this year, while coal prices have moved to year highs. The Energy Select Sector SPDR Fund or ETF (XLE) closed at $56.57, +5.07% over the last five days. The financials sector also jumped 2.3% on the backs of the rising interest rates as the 10-yr treasury yield climbed 15 basis points to 1.60% and the 2-yr yield rose to close at .31%. The U.S. Dollar Index ended at 94.12. The 3 sectors that ended lower included the real estate sector off .8%, the health care sector off .3%, & the communication services sector ticking down .1%.

Unfortunately, the small caps on the Russell 2000 did not fair as well the big boys this week and closed at 2,233.09 (-.4%), but remain up 13.1% YTD. The MicroCaps also sang a similar tune as the iShares Micro-Cap ETF (IWC) closed at $145.44, -.83% for the week, but remains up 23.58% YTD. 

MACRO REPORTS 

Many more macroeconomic reports surfaced again this week. On Monday, the Factory Orders report for August confirmed a rise of 1.2%.  On Tuesday, the ISM Non-Manufacturing Index report for September rose to 61.9%. The August Trade Balance report confirmed a widening of the trade deficit to $73.3B, a mark that greater than expected. The final IHS Markit Services PMI report rose to 54.9 in September.  On Wednesday, the ADP report estimated that private sector payrolls rose by 568k in September, number that was better than expected. The weekly MBA Mortgage Applications Index report confirmed a drop by 6.9%. On Thursday, the Initial jobless claims report for the week ending October 2 confirmed a drop by 38k to 326k & the continuing claims report for the week ending September 25 confirmed a drop by 97k to 2.714M. The Consumer credit report also confirmed a rise by $14.4B in August. On Friday, the September nonfarm payrolls report rose by 194k beige expectations, while the the unemployment rate fell to 4.8%, average hourly earnings rose by .6%, & the labor force participation rate fell to 61.6%. The wholesale inventories report confirmed a rise by 1.2% in August in line with expectations. 

Next week, the macroeconomic schedule will serve the PPI report, the unemployment rate report, & the Retail Sales growth report.

STORIES YOU MAY HAVE MISSED

Coca Cola Turns To 3 So-called Bulk Carriers As Container Rates Rise

Biotech Giant Amgen Makes Investment In Precision Medicines for Brain Diseases Focused Neumora Therapeutics

Emirates Airline Seeking Timetable Update For Boeing’s 777X Deliveries

Nike Continues To Rule As Top Choice Among Teens

McDonald’s Preparing For Zero Emissions By 2050

FAANG’s REBOUND

The FAANG’s weekly returns were as follows: Apple (AAPL) closed at $142.90, +.18%, Amazon (AMZN) closed at $3,288.62, +.16% for the week, Alphabet (GOOG) closed at $2,801.12, +2.63% for the week, Facebook (FB) closed at $330.05, -3.78% this week & Netflix (NFLX) closed at $632.66/share, +3.18%. The MicroSectors FANG+ Index 3X Leveraged ETN (FNGU), which offers 3x leveraged exposure to an index of “FANG” companies, and other companies that exhibit similar characteristics, closed at $35.90, +7.32% for the week. 

Netflix, Inc. (NASDAQ: NFLX) announced it will post its third-quarter 2021 financial results and business outlook on its investor relations website at http://ir.netflix.net on Tuesday, October 19, 2021, at approximately 1:00 p.m. Pacific Time. At that time, the company will issue a brief advisory release via newswire containing a link to the third-quarter 2021 financial results and letter to shareholders on its website.

EV- TECH 

Shares of Apple Inc. (AAPL) closed at $142.90, +.18% this week. Apple’s CarPlay interface is used by drivers to control music, obtain directions, plus make calls. Apple also now planning to expand its reach within cars as they are seeking to add technology that would control the climate-control system, speedometer, radio, & seats, via an initiative, referred to as “IronHeart” internally.

Leading EV car maker Tesla (TSLA) moved higher to close at $785.49, +1.32% for the week. Tesla, Inc. announced updates to its 2021 Annual Meeting of Stockholders Live video webcasts of the 2021 Annual Meeting event will be accessible to the general public at www.tesla.com/2021shareholdermeeting. Tesla also announced the production of approximately 238,000 vehicles & the delivery of over 240,000 vehicles in Q3. Tesla is also moving its headquarters to Austin, TX. 

Shares of Ford Motor Co. (F) moved higher to close at $15.09, +6.57% for the week. On Oct. 4th, Ford reported that new products & improved inventory have propelled Ford to “Top-Selling Automaker in September” with Retail Sales Up 34.3% Compared to August; 52,000 New Vehicle Orders Placed; Lincoln Brand Retail Sales Increase 52.6% Over August as Nautilus Sales Soar.

Microsoft (MSFT) closed at $289.10, -3.42% for the week. On October 7, Microsoft, in collaboration with private- and public-sector partners, announced the launch of Accelerate Miami-Dade. The program aims to provide a pathway from skilling to employment for Miami-Dade residents to bridge the digital skills divide and route people to diverse and equitable hiring and re-employment opportunities. Job seekers in Miami-Dade can start their journey toward their career reinvigoration today, with programs, events and opportunities available now at aka.ms/AccelerateMiamiDade.

Dow 30 component and global leader in CRM, salesforce.com (CRM), closed at $272.48, -1.01% this week. On September 23, salesforce announced a revision to its Fiscal Year 2022 revenue guidance and initiation of Fiscal Year 2023 guidance as of Sept. 23, 2021. The raised FY22 revenue guidance to a range of $26.25 billion to $26.35 billion.

NVIDIA Corporation closed lower $208.31, +.43% for the week.  On Oct. 5th, NVIDIA announced it is extending its collaboration with Lenovo to include participation in NVIDIA’s early access program in support of Project Monterey, which is designed to modernize enterprise data centers with the security and performance of NVIDIA® BlueField® data processing units. Also, Announced by VMware with NVIDIA and ecosystem partners at VMworld 2020, Project Monterey aims to improve the performance, manageability and security of enterprise data centers through the latest networking technologies, including NVIDIA BlueField DPUs. Built for AI and accelerated computing, BlueField DPUs enable delivery of applications at any scale by offloading, accelerating and isolating data center workloads.

Cathie Wood’s ARK Innovation ETF (ARKK) closed at $110.60, -.51% for the week.

The Technology Select Sector SPDR Fund (XLK) closed at $151.97, +.26% for the week.

DISNEY

Disney (DIS) closed at $176.01, +.01% for the week. Disney will discuss fiscal full year and fourth quarter 2021 financial results via a live audio webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, November 10, 2021. Results will be released after the close of regular trading on November 10, 2021. To listen to the webcast, please visit www.disney.com/investors.

BIOTECH DROPS AGAIN – $CCXI FLYS!

The Nasdaq Biotechnology ETF (IBB) closed at $155.05, -2.44% for the week & nearly down 10% in 2-weeks. The NYSE ARCA Biotech Index (^BTK) closed at 5,601.29, -1.21% for the week and is now down -2.4% YTD. In concert this week, the SPDR S&P Biotech ETF (XBI) closed at $123.44, -2.16% for the week and is off 12.32% for the year. The XBI’s 52-wk range is $109.82-$174.79.

San Carlos-based ChemoCentryx, Inc., (Nasdaq: CCXI), announced on Friday that the U.S. Food and Drug Administration (FDA) has approved TAVNEOS (avacopan), an orally administered selective complement 5a receptor inhibitor, as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (also known as ANCA-associated vasculitis or ANCA vasculitis), specifically granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) (the two main forms of ANCA vasculitis), in combination with standard therapy. ANCA-associated vasculitis is a systemic autoimmune disease in which over-activation of the complement system further activates neutrophils, leading to inflammation and eventual destruction of small blood vessels. This results in organ damage and failure, with the kidney as the major target, and is often fatal if not treated. Shares of CCXI jumped to closes at $38.41, +95.97%!

One our portfolio companies in the biotech sector, privately owned Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited iNK and CAR (Chimeric Antigen Receptor)-iNK cells derived from induced pluripotent stem cells (iPSCs) and NK cell engager multifunctional antibodies, and CytoLynx Therapeutics (“CytoLynx), its newly-formed China-focused joint venture, announced recently that they have closed $45 million from institutional investors to finance the IND enabling and initial clinical development of their pipeline. Cytovia’s management is currently targeting to go public in early-mid 2022.  Note that, Cytovia and TF Capital, a leading China-based biotech institutional investor, have formed CytoLynx Therapeutics. TF Capital along with YF Capital, BioTrack Capital, Ruihua Capital, and TG Sino-Dragon Fund (backed by TigerMed) have invested $45 million to support the new venture, as well as Cytovia research and development projects. The collaboration agreements between CytoLynx and Cytovia will advance multiple NK therapeutics through product development in the Greater China region. Additionally, CytoLynx obtained a technology license from Cytovia based on its core technologies to allow in-China development of additional NK therapeutics for global commercialization. Cytovia is eligible to receive up to $400 million in upfront development and commercial milestones under the agreement. The bankers from the largest IBanks are now circling their wagons and the valuation estimates are swelling as they consider swiftly moving forward with a Series C round with the who’s who in the world of institutional biotech investors and then pushing towards and IPO!

I hosted a FREE Tribe Public Presentation and Q&A event with INMB management on September 30, 2021. INmune Bio’s (NASDAQ: INMB) CEO Dr. Raymond J. Tesi, MD and CFO David J. Moss delivered their presentation titled “Improving White Matter Integrity In Alzheimer’s Disease” & and were available for a brief Q&A session. Please view the video now to learn more.

GOLD & SILVER

Gold prices closed at $1,759 down $3 for the week & silver prices closed at $22.69, +$.12/oz for the week.

MEMES REPORT

AMC Entertainment (AMC), closed at $37.19, -3.30% for the week. On Monday, AMC announced that it just set a new post-reopening record for weekend attendance (Thursday through Sunday), as well new post-opening records for ticket admission revenues and food & beverage sales. This was driven by the openings of VENOM: LET THERE BE CARNAGE in the United States and the latest James Bond movie, NO TIME TO DIE, overseas.

GameStop (GME) closed at $172.68, -2.39% for the week. 

Virgin Galactic Holdings (SPCE) closed at $23.12, -2.98% for the week. On Wednesday SPCE, a vertically integrated aerospace and space travel company, announced that it is cleared to fly FAA-licensed spaceflights following the conclusion of an FAA inquiry that focused on air traffic control clearance and real-time mission notification related to the Unity 22 flight in July. Michael Colglazier, Chief Executive Officer of Virgin Galactic, said: “Our entire approach to spaceflight is guided by a fundamental commitment to safety at every level, including our spaceflight system and our test flight program. We appreciate the FAA’s thorough review of this inquiry. Our test flight program is specifically designed to continually improve our processes and procedures. The updates to our airspace and real-time mission notification protocols will strengthen our preparations as we move closer to the commercial launch of our spaceflight experience.”

Infamous ‘meme brokerage’ firm Robinhood Markets, Inc., (HOOD) moved higher this week closing at $41.78, -.29% for the week & still higher then IPO shares which were sold at $38 this year! The HOOD had 22.5 million funded accounts at the end of June.

Seanergy Maritime Holdings Corp. (NASDAQ: SHIP) closed at $1.38, -3.5% for the week. SHIP is the ‘only pure-play Capesize ship-owner publicly listed in the US’, recently announced that its Board of Directors has authorized a share repurchase plan. Under the Plan, the Company may repurchase up to $17 million of its outstanding common shares, representing approximately 10% of the Company’s market capitalization as of August 10, 2021.

BITCOIN REPEATS

Bitcoin $BTC.X closed at $54,142.62, up another 10.24% after last weeks +9.97% weekly. Bitcoin has flown an amazing 86% this year. 

SOLAR ACQUISITION  

On October 5, SunPower Corp. (NASDAQ: SPWR, $23.96), a leading solar technology and energy services provider, announced it acquired Blue Raven Solar, one of the fastest growing residential solar providers in the U.S. Blue Raven’s growth trajectory and complementary geographic footprint is expected to provide SunPower a path to quickly expand the solar market to serve more customers in underpenetrated areas including the Northwest and Mid-Atlantic regions.
“More than 100 million homeowners could save money by switching to solar today, and we are committed to enabling that transition quickly to benefit both customers and the planet,” said Peter Faricy, CEO of SunPower. “SunPower and Blue Raven share a vision of powering the world with affordable, resilient, sustainable energy. This acquisition will enable us to bring the most powerful and efficient solar technology available to a new set of homeowners and accelerate our growth strategy.” The acquisition was made for cash consideration of up to $165 million. Blue Raven CEO Ben Peterson will join SunPower’s executive team, and the company expects to build upon Blue Raven’s current employee and contractor relationships. Since its founding in 2014, Blue Raven has built a profitable and high-growth business, achieving 93% revenue compound annual growth rate (CAGR) with a direct-to-consumer sales and installation model. Blue Raven currently conducts more than 90% of its volume in 14 states that account for only about 5% of SunPower’s sales, creating a significant net-new geographic coverage opportunity for SunPower.

The Energy Select Sector SPDR Fund or ETF (XLE) closed at $56.57, +5.07% over the last five days.
 

NEXT WEEK

The stock market will enjoy another normal 5-day trading week, however, the bond market is closed on Monday to observe the Columbus Day holiday.  

VP WATCHLIST UPDATES

Please review our complete VP Watchlist that includes Apple (AAPL), Disney (DIS), Tesla (TSLA) & a select group of emerging names.  The pages will allow you to learn more and keep up with these companies daily.

For now, see the summaries or five of the emerging companies from the VP Watchlist below:


  • Shares of INmune Bio, Inc. (NASDAQ: INMB) moved higher closing at $17.28, -15.21% this week. The 52-wk range is $7.28 – $29.99.
    • I hosted a FREE Tribe Public Presentation and Q&A event with INMB management today, Thursday, September 30 at 8:30am PT/11:30am ET. INmune Bio’s (NASDAQ: INMB) CEO Dr. Raymond J. Tesi, MD and CFO David J. Moss delivered their presentation titled “Improving White Matter Integrity In Alzheimer’s Disease” & and were available for a brief Q&A session. Please view the video now to learn more.

    • On Wednesday, Aug. 4th, INmune Bio, Inc. reported its financial results for the second quarter ended June 30, 2021 and provided a business update. Raymond J Tesi, M.D., CEO/CMO of INmuneBio (INMB) stated, “We continue our planning and setup for a Phase 2 clinical trial of our lead candidate, XPRO™ (Xpro1595™), in patients with mild Alzheimer’s disease, which we plan to initiate by year-end. We have already demonstrated that XPRO™ can reduce neuroinflammation and decreases biomarkers of neurodegeneration and improve synaptic function. If successful in Phase 2, we believe XPRO™ has the potential to be among the most significant advancements in the treatment of Alzheimer’s Disease (AD) and other neurodegenerative diseases in many years. At the Alzheimer’s Association International Conference last week, we introduced a new biomarker – Apparent Fiber Density (AFD), a measure of axonal integrity measured by MRI. XPRO™ increases AFD in patients receiving 1mg/kg/week. We believe the novel non-invasive white matter analytics of white matter free water and apparent fiber density will be very useful in the development of XPRO™ in AD, Treatment Resistant Depression (TRD) and the many other CNS indications we hope to attack in the future. Last month, we treated the first patient in the first Phase 1 clinical trial of our NK cell priming platform, INKmune, in high-risk myelodysplastic syndrome (MDS). We are calling INKmune a pseudokine because, in vitro, it converts the resting NK cells into memory-like NK cells that can kill cancer cells as well or better than NK cells treated cytokines such as IL-12, IL-15 and IL-18 alone or in combination.”
    • On July 26th, INmune Bio announced the design of its upcoming Phase 2 clinical trial of XProTM in patients diagnosed with mild Alzheimer’s disease (AD) at AAIC. The announcement was accompanied by the release of additional biomarker data from the Phase 1b AD trial that shows improvement in white matter (myelinated axons) that degenerate in AD patients. READ MORE. 
    • On July 22, LUMICKS, a leading next generation life science tools company renowned for its innovative platforms for Dynamic Single-Molecule and Cell Avidity analysis, announced that it has installed its ground-breaking z-Movi® Cell Avidity Analyzer at INmune Bi0. INmune Bio is employing the z-Movi cell avidity analysis platform to demonstrate that the mechanism of action of the tumor-priming is the increase in NK cell:tumor cell avidity. Early data acquired by the z-Movi support their hypothesis that increased cell avidity enhances NK cell killing of tumor cells. This allows screening of batches of INKmune for potency and provides a potential biomarker of in vivo activity by measuring the tumor avidity of NK cells isolated from patients before and after INKmune treatment.
    • On July 14th, INmune Bio announced that it has entered into a definitive agreement with one healthcare focused institutional investor and one family office for the purchase and sale of 1,818,182 shares of its common stock at a price of $22 per share for gross proceeds of approximately $40 million in a registered direct offering. The closing of the offering is expected to occur on or about July 16, 2021, subject to the satisfaction of customary closing conditions. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering. INmune Bio intends to use the net proceeds from this offering for working capital and general corporate purposes and to advance the development of its product candidates and expand its pipeline. This includes the completion and data readout from the Company’s planned Phase 2 clinical trial of its lead clinical candidate, XPro1595, in patients suffering from Alzheimer’s disease, which is expected to commence by the end of 2021. “With this investment, we expect the Company’s Phase II program in Alzheimer’s disease is completely funded said RJ Tesi MD, CEO of Inmune Bio.
    • On July 12th,  INmune Bio, Inc. announced that the first patient has been treated in the company’s Phase 1 clinical trial of its Natural Killer (NK) cell priming platform, INKmune, as a potential treatment for high-risk myelodysplastic syndrome (MDS). This Phase 1 open label study will enroll nine patients with a confirmed diagnosis of MDS with excess blasts in a 3×3 dose escalation protocol. The primary endpoint is the safety and tolerability of INKmune when administered intravenously. Most secondary endpoints are biomarkers and include the change in percentage of blasts in peripheral blood and bone marrow, the change in autologous NK cell activity and functional maturity into tumor-induced memory-like NK cells in vivo. The overall response rate using WHO criteria, and duration of response will also be reported. READ MORE.
    • On July 7th, The Maxim Group’s analyst raised his price target from $32 to $42 today.
    • On June 14th, INMB announced that it had entered into a new $15M credit facility with Silicon Valley Bank (SVB) and an affiliate of SVB Financial Group. INmune intends to use the proceeds from the facility to partially fund the buyout of an option held by Xencor, Inc.(XNCR), resulting from INmune’s in-licensing of XPro1595 (now known by its generic name, pegipanermin) in October 2017. XPro1595 is a next-generation inhibitor of tumor necrosis factor (TNF) that uses a dominant-negativeTNF technology that is very different from approved TNF inhibitors that block the effects of both soluble and trans-membrane TNF. Pegipanermin neutralizes soluble TNF, without affecting trans-membrane TNF or TNF receptors. XPro1595 could have substantial beneficial effects in patients with Alzheimer’s and other neurodegenerative diseases by decreasing neuroinflammation. Total consideration to be paid to Xencor by INmune is $18.3 million, comprised of $15 million of cash and $3.3 million of INMB shares at a price of $17.14 resulting in the issuance of 192,533 shares. Pursuant to the original 2017 in-licensing agreement, INmune granted Xencor an option to purchase an additional number of shares of common stock equal to 10% of INmune’s fully diluted company shares for a period of seven years. The retirement of the Xencor option eliminates an estimated 2.1 million shares of potential future common stock dilution upon exercise of the option.



  • InMed Pharmaceuticals, Inc. (NASDAQ: INM) is leading clinical-stage pharmaceutical company developing cannabinoid-based drug candidates for high unmet medical needs and IntegraSyn, a proprietary and cost effective manufacturing approach for synthesized rare cannabinoids. Please visit the INM page at our website to learn more and check out the videos section too.  
  • Shares of InMed closed trading this week at $1.51, -11.18% for the week. The 52-wk range is $1.45 – $8.94. 
    • On September 30, INmed announced that it has commenced its Phase 2 clinical trial of INM-755 (cannabinol) cream in the treatment of Epidermolysis Bullosa (“EB”). This marks the first time cannabinol has advanced to a Phase 2 Clinical trial to be studied as a therapeutic option to treat a disease. This study will be taking place at eleven sites across seven countries including Austria, Germany, Greece, France, Italy, Israel and Serbia. Clinical Trial Applications (“CTAs”) have been filed in all participating countries with regulatory authority and ethics committee approvals currently in place in four countries (Austria, France, Greece, Israel). The first site initiation visit was completed at a clinical site in Austria, where screening for eligible patients will begin shortly. “The start of this Phase 2 clinical trial represents a very important step forward to test the efficacy of INM-755 (cannabinol) cream in treating epidermolysis bullosa, a disease that has very few treatment options,” stated Alexandra Mancini, Senior Vice President of Clinical and Regulatory Affairs at InMed. “Based on our earlier studies, we are hopeful that our cannabinol cream will prove to be a safe and effective treatment for people living with this severe genetic skin disease.”

    • I hosted INM’s management team on the Tribe Public Network on Tuesday, September 21 for a 30-minute FREE Presentation and Q&A Webinar Event. Eric A. Adams, MIBS, CEO & President of InMed Pharmaceuticals (NASDAQ: INM) & Shane Johnson, MD, Co-Founder of BayMedica delievered a presentation titled “Accelerating The Commercialization of Rare Cannabinoids.” They held a Q&A session at the end of the presentation. You may view the video of the event at the Tribe Public YouTube Channel here.
    • On Friday morning, September 24,  InMed reported their full year Fiscal 2021 financial results and provided a business update. The Company’s full financial statements and related MD&A for the fiscal year ended June 30, 2021, are available at www.inmedpharma.com, www.sedar.com and at www.sec.gov. Eric A. Adams, InMed CEO, stated, “In the final quarter of our of fiscal year 2021, as well as throughout the year, we made important progress in corporate development, pharmaceutical drug development and in advancing our proprietary manufacturing approach, IntegraSyn™. With the recent announcements regarding our acquisition of BayMedica Inc., the Company is well positioned to continue its activities to solidify a leadership position in the field of rare cannabinoids.”
    • On September 13th, InMed announced that it has entered into a definitive agreement  to acquire BayMedica Inc., a private company based in the US that specializes in the manufacturing and commercialization of rare cannabinoids. The Definitive Agreement follows a previously signed letter of intent announced on June 29, 2021. The transaction, which is subject to certain standard closing conditions, is expected to close in the coming weeks. Upon closing, InMed will become a global leader in the manufacturing of rare cannabinoids, with expertise in three distinct and complementary cannabinoid manufacturing approaches. InMed’s proprietary cannabinoid manufacturing process, IntegraSyn™, combined with BayMedica’s synthetic biology and chemical synthesis capabilities, will provide InMed with complete manufacturing flexibility to select the most appropriate, cost-effective method based on the target cannabinoid and appropriate quality specifications for the desired market segment. In parallel to cannabinoid manufacturing, the combined company will continue to explore the therapeutic potential of cannabinoids and novel cannabinoid analogs for pharmaceutical drug development, as well as expand commercial sales of rare cannabinoids to the consumer health and wellness sector. Revenues of BayMedica’s initial rare cannabinoid product, Prodiol® CBC (cannabichromene), have grown steadily since sales commenced in December 2019, with cumulative revenues in excess of US$2.5M. BayMedica leads the industry in large batch production of CBC with current batch sizes of more than 200kg and an ability to increase to metric ton quantities as market demand increases. BayMedica is focused on the wholesale to consumer health and wellness markets, including nutraceuticals, cosmetic, functional food and beverage, as well as animal health markets. In addition to CBC, BayMedica has several high value non-intoxicating rare cannabinoids in various stages of commercial manufacturing scale-up including CBDV, THCV, CBGV, CBT and CBN for the health and wellness markets.
    • On July 9th, Roth Capital Partners analyst Scott Henry, CFA issued an update report with. BUY Rating titled, “INM: Favorable Take on BayMedica LOI” that includes a $11.50 12-Month Price Target.
    • On July 2, InMed announced that it had closed the previously announced private placement and after deducting the placement agent fees and estimated offering expenses payable by the Company, the Company received net proceeds of approximately US$11 million. H.C. Wainwright & Co. acted as the exclusive placement agent for the private placement. Under the terms of the private placement, an aggregate of 4,036,327 common shares (or common share equivalents in lieu thereof) and warrants to purchase up to an aggregate of 4,036,327 common shares were purchased, at an effective purchase price of US$2.973 per common share (or common stock equivalent in lieu thereof) and associated warrant. The warrants have an exercise price of US$2.848 per share, are exercisable immediately and have a term of five years. InMed intends to use the net proceeds from the offering to continue pipeline development, advance business development activities and for general working capital purposes.

    • On Thursday, June 17th, InMed Pharmaceuticals (NASDAQ: INM) announced that its continued optimization of IntegraSyn™ has increased the cannabinoid yield to a level of 5 g/L, further improving the economics of this proprietary manufacturing approach in advance of large-scale production. InMed’s cannabinoid yield of 5 g/L significantly exceeds currently reported industry yields. The Company has continued to make important steps to further optimize the IntegraSyn™ manufacturing process, resulting in the improved yield of 5 g/L, surpassing InMed’s previously reported yield levels of 2 g/L, an already commercially viable yield. The impact of improved yield is a significant reduction in the overall cost of manufacturing due to greater amount of cannabinoid produced per batch. InMed is now focused on manufacturing scale-up to larger batch sizes in the second half of calendar year 2021. “We are very excited by these impressive yield levels that further validates the IntegraSyn™ manufacturing approach as a commercially viable solution for large-scale, pharmaceutical-grade GMP production of rare cannabinoids. While we continue to refine the process, we are now focused on advancing the program towards the next key milestones, including the manufacture of our first large-scale batch through a GMP-ready process in the coming months. We continue to believe InMed’s proprietary IntegraSyn™ approach will be one of the most important manufacturing processes for pharma-grade cannabinoids,” stated Eric A. Adams, President and Chief Executive Officer of InMed.


  • Shares of Natural-Killer cell (NKcell) focused biopharmaceutical firm Fate Therapeutics (FATE) closed at $54.93, -7.68% for the week. The 52-wk high is $121.16.
    • On Oct. 1, Fate announced that one oral and four poster presentations for the Company’s induced pluripotent stem cell (iPSC) product platform were accepted for presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held November 10-14, 2021. The oral presentation will highlight preclinical data for FT536, the Company’s off-the-shelf, multiplexed-engineered, iPSC-derived, chimeric antigen receptor (CAR) NK cell product candidate that uniquely targets the α3 domain of the MHC class I related proteins A (MICA) and B (MICB). In a recent publication in Cancer Immunology Research (DOI: 10.1158/2326-6066.CIR-19-0483), Kai W. Wucherpfennig, M.D., Ph.D., Chair of the Department of Cancer Immunology and Virology at the Dana-Farber Cancer Institute and co-leader of the Cancer Immunology Program at Dana-Farber / Harvard Cancer Center, demonstrated that cancers with loss of MHC Class I expression can be effectively targeted with MICA/B α3 domain-specific antibodies to restore NK cell-mediated immunity against solid tumors. The FT536 program is supported by an exclusive license from the Dana-Farber Cancer Institute to intellectual property covering novel antibody fragments binding MICA/B for iPSC-derived cellular therapeutics. The Company expects to submit an Investigational New Drug (IND) application for FT536 in the fourth quarter of 2021 for the treatment of advanced solid tumors, including in combination with monoclonal antibody therapy.
    • On September 15, Fate Therapeutics announced the publication of preclinical data demonstrating that its off-the-shelf, multiplexed-engineered, iPSC-derived NK cell product candidate FT538 exhibits significantly enhanced serial killing and functional persistence compared to peripheral blood NK cells. The superior anti-tumor activity of FT538 was attributable to its novel engineered components, including the knockout of CD38 and the expression of IL-15/IL-15R fusion protein, which were shown to improve metabolic fitness, increase resistance to oxidative stress, and induce transcription of proteins that control NK cell activation and effector function. The data were published in Cell Stem Cell in an online article entitled “Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy”.


  • Shares of Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, closed at closed at $3.18, -2.15% for the week. 
    • On September 30, September 30, Atossa announced it has begun to enroll participants in its clinical study of AT-H201 in Australia. The nebulized formulation, AT-H201, is being developed as an inhalation therapy for moderately to severely-ill hospitalized COVID-19 patients and for “long-haul” patients with post-infection pulmonary disease. “Even with vaccines becoming widely available, the COVID-19 pandemic continues to be an urgent global health crisis,” said Steven Quay, M.D., Ph.D., Atossa’s CEO and President. “Enrolling the first two participants in this study marks a significant milestone in our goal of ultimately developing nebulized AT-H201 to improve lung function in patients with active disease, which may reduce the number of patients requiring ventilators, and in ‘long-haul’ patients who have residual pulmonary function damage. Up to one third of hospitalized patients have pulmonary function changes 60 days or more after recovering from COVID. The portability of nebulizers, already routinely used for other chronic lung disease, should allow for treatment at home.”
    • On September 8th, Edward Woo, analyst at Ascendiant Capital Markets issued an update report titled “Q2 about inline. COVID-19 and breast cancer clinical trials expected to start soon should be catalysts for stock” and raided his P/T to $8.50.
    • On Aug 13th, Atossa announced financial results for the fiscal quarter ended June 30, 2021, and provided an update on recent company developments. “We continue to experience encouraging progress in our MBD and COVID-19 programs, with new regulatory approvals being granted in Sweden for a Phase 2 trial in MBD and authorization in Australia to commence a Phase 2 study of AT-H201 for respiratory illness associated with COVID-19. In the meantime, we continue to enjoy a strong balance sheet, which we have significantly expanded over the last three quarters and will facilitate our development plans over the near term. As we actively explore the possibility for strategic expansion into other areas where we might see near-term milestones and results, we also urge all of our shareholders to exercise their right to vote at our special stockholder’s meeting on September 7, 2021. We urge a vote in favor of the proposal to increase authorized shares, which will provide the Company with the flexibility to issue shares as part of these potential acquisitions, collaborations and partnerships, a common strategy successful biotech companies seeking to grow shareholder value employ in order to create a more attractive opportunity for all. We look forward to continuing to update our stockholders on these opportunities as they develop,” stated Dr. Steven Quay, Atossa’s President and Chief Executive Officer.
  •  

  • Shares of  INVO Bioscience, Inc. (INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world’s only in vivo Intravaginal Culture System, closed at $4, +18.34% for the week.  
    • On Oct. 1, INVO announced that it has entered into definitive agreements with institutional and accredited investors and members of INVO Bioscience’s management team to purchase 1,240,763 shares of its common stock at a purchase price of $3.26 per share, in a registered direct offering priced at-the-market under Nasdaq rules, for gross proceeds of approximately $4.0 million. The registered direct offering is expected to close on or about October 5, 2021, subject to the satisfaction of customary closing conditions.
      • The group of investors includes members of INVO Bioscience’s management team, including Steve Shum, CEO, and Andrea Goren, CFO. Paulson Investment Company, LLC is acting as the exclusive placement agent for the offering. The gross proceeds from the offering are expected to be approximately $4.0 million, before deducting placement agent’s fees and other offering expenses. INVO Bioscience currently intends to use the net proceeds from this registered direct offering for general corporate and working capital purposes.
      • Also, on Oct. 1, INVO entered into a separate Stock Purchase Agreement with Paradigm Opportunities Fund, LP an accredited institutional investor, pursuant to which we will issue to such investor 600,703 shares of their common stock, par value $0.0001 per share for a purchase price of $3.329 per share for an aggregate purchase price of $1,999,740.29. This transaction is set to close on November 30, 2021. The Shares will be issued under the exemption from registration under Section 4(a)(2) and/or Rule 506 of the Securities Act of 1933, as amended. The Purchase Agreement contains a $250,000 break-up fee whereby if either party fails to close, it will be required to pay the non-breaching party a fee of $250,000. The investor under the Purchase Agreement also agreed to a 1-year lock up period with respect to the Shares.
    • On September 9th, INVO Bioscience announced that it has completed the acquisition of a Canadian-based entity that was originally formed to offer INVOcell in Canada. The entity had previously completed a number of important procedures and documentation necessary to establish INVOcell within clinical operations in Canada. INVO Bioscience anticipates leveraging this entity to advance the distribution of INVOcell, and take advantage of the existing product registration which approved the device for sale based on 5-day incubation in the Canadian market. In addition, the Company is initiating the development of joint ventures to establish INVO Centers within the Canadian marketplace, similar to U.S. and Mexico markets, to further drive accelerated adoption of the INVOcell solution while also increasing much needed capacity and patient access within the fertility industry. Steve Shum, CEO of INVO Bioscience, commented, “We believe Canada offers an excellent opportunity to further expand our distribution efforts of INVOcell while also advancing our joint-venture based INVO Center model. With roughly 16% (or 1 in 6) couples in Canada experiencing infertility, a number that has doubled since the 1980s, and with a popultion of 37.74 million, Canada represents a sizable market opportunity. Canada also faces similar issues that hamper other parts of the world, including a large underserved population, access/capacity constraints and affordability challenges. We appreciate the key individuals in Canada that originally created this entity to help promote and bring our INVOcell technology into the marketplace and look forward to bringing greater resources to advance this effort. We anticipate this acquisition will serve as a platform to help accelerate building INVOcell’s presence in Canada.”
    • On September 7th,  INVO Bioscience announced that it has officially opened the Company’s 2nd INVO Center in the United States, based in Atlanta, Georgia after recently opening their first in Birmingham, AL called “Innovative Fertility Specialists, An INVO Center” on August 9th. INVO Centers are further scheduled this year to open in Monterrey, Mexico & the San Francisco Bay Area. This new joint-venture, named “Bloom Fertility, an INVO Center,” will focus on patients in need of advanced fertility care utilizing the efficient, effective, and affordable INVOcell solution. READ THE COMPLETE STORY. 

    • On August 16th, INVO announced their financial and operating results for the second quarter ended June 30, 2021 and provided a business update. Steve Shum , CEO of INVO stated. “Our team made excellent progress during the second quarter of 2021 toward our key objectives, headlined by last week’s official opening of our first INVO Center practice in Birmingham, AlabamaWe feel INVO is now well positioned for success based on the following core foundational elements developed over the past 2 years. We believe there is a substantial underserved patient population with infertility challenges and a real need to expand access to treatment. In our opinion, this is a multi-billion-dollar market expansion opportunity, and INVOcell is well positioned to address the unmet medical need.”
    • On Aug.2, INVO announced the Company’s first Joint Venture INVO Center practice in the United States, based in Birmingham, Alabama, will officially open on August 9, 2021. Dr. Hammond commented, “With the opening of the country’s first INVOcell medical practice, we are advancing a core mission towards improving access to advanced fertility services for the many patients who would otherwise never have the opportunity. To date, we have already received numerous advanced inquiries via word of mouth and have dozens of patients scheduled for initial patient consultations who are eager to proceed with treatment. As we officially open the center next week, we expect to accelerate our marketing programs with the help of the INVO marketing team to enhance overall patient awareness around Innovative Fertility Specialists, An INVO Center.”

INVO

    • On June 30th, VP Watchlist company, INVO Bioscience, Inc. (NASDAQ: INVO) expanded their North American footprint as they announced on June 30th that they had signed a joint venture agreement in partnership with reproductive specialist Dr. Sue Ellen Carpenter, M.D. through its wholly-owned subsidiary, INVO Centers, LLC, to open an INVO clinic in Atlanta. The clinic, Bloom Fertility, is scheduled to open in the second half of 2021. INVO Bioscience will provide funding for start-up and operating costs and own 40% of the Atlanta Joint Venture. Dr. Sue Ellen Carpenter, MD, is Board Certified in Obstetrics and Gynecology. With over 30 years of experience in reproductive medicine, Dr. Carpenter’s specialties include in vitro fertilization, treating congenital anomalies associated with infertility, as well as endometriosis and polycystic ovarian syndrome. Noted for excellence in her field and a “Top Doctor, Atlanta 2019 and 2020″ she delivers lectures across the country and has published more than a dozen papers on reproduction and fertility. She is an active member of the American Society of Reproductive Medicine (ASRM) as well as the Georgia OB GYN Society. Note that INVO Bioscience has also signed clinic partnerships in Birmingham, Alabama and the San Francisco Bay area earlier this year, along with its Mexico partnership in late 2020, which is scheduled to open later this year. These clinics, through the utilization of the INVOcell technology, in addition to the multiple clinic and distribution partnerships throughout the world are bringing advanced fertility care and much needed expanded access to the millions of underserved people.
    • On June 15th, INVO Bioscience, Inc. (NASDAQ: INVO), announced further foundational progress as they appointed of Andrea Goren as the Company’s Chief Financial Officer. In a career approaching 27 years, Mr. Goren has extensive experience in numerous financial functions, including service as a public company CFO, company director, capital raising activities as well as mergers and acquisition experience. Mr. Goren has served as managing director and CFO of Phoenix Group, a New York City-based private equity firm specializing in micro-cap and nano-cap public companies. He served as vice president of Shamrock Group, the Roy Disney family private investment firm in London; and was a director at New York City-based Madison Capital Group, a corporate advisory firm focused on U.S. / European Union cross border transactions. Mr. Goren holds a Bachelor of Arts degree from Connecticut College in New London, Connecticut, and an MBA from the Columbia Business School in New York City.
    • On May 17, INVO announced financial results for the first quarter of 2021 ended March 31, 2021 and provides a business update. Steve Shum, Chief Executive Officer of INVO Bioscience stated, “This was an exciting start to the year 2021 for INVO Bioscience as we advanced our INVO Clinic strategy with the signing of our first U.S.-based INVOcell exclusive facility in Birmingham, Alabama, the signing of a partnership agreement to establish and operate a center in Northern California, and the completion of our product registration in Mexico. We expect these initial centers to become operational in the second half of the year. Throughout this year, we have expanded our real-world experience data and positive results with INVOcell, enhanced our online training tools, materials, and capabilities and have experienced a substantial increase in active training sessions for our international partners and distributors. We believe the combination of strong commercialization partnerships and company-owned clinics, both in the U.S. and around the world, is key to expanding INVOcell’s adoption within the fertility industry. In addition to the progress made executing new commercialization agreements, we have strengthened our marketing capabilities to support the INVOcell-only centers and our growing number of distribution partners. Meryle Lynn Chamberlain, a tenured women’s health and fertility solution marketing professional, joined us as Director of Marketing in March 2021, while Rebecca Messina, current Senior Advisor at McKinsey & Co. and former Global Chief Marketing Officer at both Uber and Beam Suntory joined our board of directors in April 2021. As we look to increase access to care and expand fertility treatment across the globe, our market positioning and overall strategies are more important than ever. The addition of Meryle Lynn and Rebecca will enhance our ability to successfully accomplish these goals. As we look to the remainder of 2021, we have set a number of key objectives, including the opening of our first company-owned clinics in Mexico and the United States. Additionally, we will seek to build our international revenues this year through our growing list of international distribution partners as they finish training, and we complete local product registration requirements. Of note, we are extremely pleased to see the initial INVO procedures performed recently in Spain and Malaysia, which reflects the groundwork done by our team in these specific markets, which we believe will help in further expanding the overall awareness of the potential outside of the U.S. Finally, we are continuing to advance our 5-day label expansion efforts with the FDA in the U.S. market with a goal of completing this effort in 2021. It remains our belief that there is strong global demand for fertility services and INVOcell is well-positioned through our growing, global footprint to play a key role in helping to turn the dream of creating a family for millions of people around the world into a reality through our accessible, efficient, and affordable fertility treatment.”
    • On May 11, a 13G was filed that confirms that David Sable’s (a former #IVF doc turned portfolio manager) Special Situations Fund of AWM Investment Company increased their ownership to 11.1% or 1,154,153 share ownership of INVO Bioscience (INVO). They held 625k/6.5% as of the 13G filing 2-12-2021. If you are not familiar with them, I believe if you do a relatively small amount sleuthing you will find out that they are one of the most successful multi-billion funds over the last 20-years, especially in finding small undiscovered microchips. I believe that they led the round of $13M at $3.20 a share in November 12, 2020 that pushed INVO uplist to the NASDAQ. Here’s the 13G filing. The company only has 10,424,229 shares issued and outstanding as of March 31, 2021.
    • Industry forecasts suggest that only 1% to 2% of the estimated 150 million infertile couples worldwide are currently being treated. INVO’s mission is to increase access to care and expand infertility treatment across the globe with a goal of improving patient affordability and industry capacity. Since January 2019, INVO Bioscience has signed commercialization agreements in the United States, India, as well as parts of Africa and Eurasia and Mexico for the INVOcell device.


Thanks again for your attention this week. Please continue to share your thoughts, questions, & ideas as we move forward. 

In the meantime, please enjoy the balance of the weekly newsletter’s videos, quotes, updates. 

Markets

Symbol Name Last Price Change % Change

Big Movers

Symbol Name Last Price Change % Change

Bond Markets & US Dollar

Symbol Name Last Price Change % Change

Agriculture & Energy

Symbol Name Last Price Change % Change

Biotech & Healthcare

Symbol Name Last Price Change % Change

Consumer Goods & Trends

Symbol Name Last Price Change % Change

Financials & Fintech

Symbol Name Last Price Change % Change

Materials & Natural Resources

Symbol Name Last Price Change % Change

Technology & Beyond

Symbol Name Last Price Change % Change

Investing & Inspiration

  1. “The deal machinations many companies put themselves through, while certainly a bonanza for investment bankers, can confound the typical investor.” – Whitney Tilson
  2. “Nothing is impossible, the word itself says ‘I’m possible’!” – Audrey Hepburn
  3. “Procrastination is the art of keeping up with yesterday.” – Don Marquis
  4. “Do not fear mistakes. You will know failure. Continue to reach out.” – Benjamin Franklin

  5. “Success is peace of mind which is a direct result of self-satisfaction in knowing you did your best to become the best you are capable of becoming.” – John Wooden
  6. “One fails forward toward success.” – Charles Kettering
  7. “The greater danger for most of us lies not in setting our aim too high and falling short; but in setting our aim too low, and achieving our mark.” – Michelangelo
  8. “I hear and I forget. I see and I remember. I do and I understand.” – Confucius
  9. “I’m a very strong believer in listening and learning from others.” – Ruth Bader Ginsburg
  10. “Blessed are those who give without remembering and take without forgetting.” – Elizabeth Bibesco
  11. “As you walk down the fairway of life you must smell the roses, for you only get to play one round.” – Ben Hogan
  12. “Progress is man’s ability to complicate simplicity.” – Thor Heyerdahl
  13. “Economics is all about consumption. People either spend money now or they use financial instruments – like bonds, stocks and savings accounts – so they can spend more later.” – Adam Davidson
  14. “Ever tried. Ever failed. No matter. Try Again. Fail again. Fail better.” -Samuel Beckett
  15. “In the post-industrial economy, ideas and great minds often provide far greater return on investment than any other resources or capital investments.” – Marvin Ammori
  16. “Work like you don’t need the money. Love like you’ve never been hurt. Dance like nobody’s watching.” – Satchel Paige
  17. “One of the rules I’ve learned is that struggling to try and think your way into making an investment is usually the best way to not have a great outcome.” – Stephen A. Schwarzman
  18. “The secret of business is to know something that nobody else knows.” – Aristotle Onassis
  19. “It takes a long time to grow an old friend.” – John Leonard
  20. “Life is a dream for the wise, a game for the fool, a comedy for the rich, a tragedy for the poor.”– Sholom Aleichem
  21. “The truth is you don’t know what is going to happen tomorrow. Life is a crazy ride, and nothing is guaranteed.” – Eminem
  22. “Man is only great when he acts from passion.” – Benjamin Disraeli
  23. “We need to stop thinking about infrastructure as an economic stimulant and start thinking about it as a strategy. Economic stimulants produce Bridges to Nowhere. Strategic investment in infrastructure produces a foundation for long-term growth.” – Roger McNamee
  24. “We must let go of the life we have planned, so as to accept the one that is waiting for us.” – Joseph Campbell
  25. “Put your heart, mind, and soul into even your smallest acts. This is the secret of success.” – Swami Sivananda
  26. “I can’t change the direction of the wind, but I can adjust my sails to always reach my destination.” – Jimmy Dean
  27. “Companies have too many experts who block innovation. True innovation really comes from perpendicular thinking.” – Peter Diamandis
  28. “By failing to prepare, you are preparing to fail.” – Benjamin Franklin
  29. “We cannot solve our problems with the same thinking we used when we created them.” – Albert Einstein
  30. “When you’re an investor, you can look at the quantitative and qualitative elements of an investment, but there’s a third aspect: What you feel in your gut.” – Kevin O’Leary
  31. “Set your course by the stars, not by the lights of every passing ship.” – Omar N. Bradley
  32. “Do not take life too seriously. You will never get out of it alive.” – Elbert Hubbard
  33. “Education is not only a ladder of opportunity, but it is also an investment in our future.” – Ed Markey 
  34. “Every good painter paints what he is.” – Jackson Pollock
  35. “If you believe in yourself and have dedication and pride – and never quit, you’ll be a winner. The price of victory is high but so are the rewards.” – Bear Bryant
  36. “Your mindset matters. It affects everything – from the business and investment decisions you make, to the way you raise your children, to your stress levels and overall well-being.” – Peter Diamandis
  37. “You cannot have a positive life and a negative mind.” – Joyce Meyer 
  38. “Like wildebeest and zebra migration across the Serengeti, investment managers and consultants, too, have a habit of running together and, every now and then, changing direction.” – Sanjaya Baru
  39. “If people are anything but enthusiastic about the information or ideas that they’re sharing, they’re either not that invested in what they’re doing – or they’re not communicating that investment effectively.” – Ana Kasparian 
  40. “Life consists not in holding good cards but in playing those you hold well.” – Josh Billings 
  41. “Friend, there’s no greater investment in life than in being a people builder. Relationships are more important than our accomplishments.” – Joel Osteen
  42. “It’s only natural that the heavy users help contribute to the investment to keep the Web healthy. That is the most important concept of net neutrality.” – Lowell McAdam
  43. “The more sand that has escaped from the hourglass of our life, the clearer we should see through it.” – Jean Paul 
  44. “Eliminate emotion from your investment program.” -John C. Bogle

  45. “Modern medical advances have helped millions of people live longer, healthier lives. We owe these improvements to decades of investment in medical research.” – Ike Skelton
  46. “In every investment, before I get involved or invest, I always see what the mindset of the founder, the CEO, is.” – Zaza Pachulia
  47. “An investment said to have an 80% chance of success sounds far more attractive than one with a 20% chance of failure. The mind can’t easily recognize that they are the same.” – Daniel Kahneman
  48. “The return on investment in global health is tremendous, and the biggest bang for the buck comes from vaccines. Vaccines are among the most successful and cost-effective health investments in history.” – Seth Berkley
  49. “Few things in the world are more powerful than a positive push. A smile. A world of optimism and hope. A ‘you can do it’ when things are tough.” – Richard M. DeVos
  50. “To be yourself in a world that is constantly trying to make you something else is the greatest accomplishment.” – Ralph Waldo Emerson
  51. “We all have dreams. But in order to make dreams come into reality, it takes an awful lot of determination, dedication, self-discipline, and effort.”  – Jesse Owens
  52. “The pessimist complains about the wind; the optimist expects it to change; the realist adjusts the sails.” – William Arthur Ward- American Writer, Born 1921
  53. “Once you replace negative thoughts with positive ones, you’ll start having positive results.” – Willie Nelson
  54. “The secret of your future is hidden in your daily routine.” – Mike Murdock
  55.  “If somebody puts you down or criticizes you, just keep on believing in yourself and turn it into something positive.” – Leah LaBelle
  56. “Opportunity is missed by most people because it is dressed in overalls and looks like work”. -Thomas A. Edison
  57. “Education is not only a ladder of opportunity, but it is also an investment in our future.” – Ed Markey
  58. “Human behavior flows from three main sources: desire, emotion, and knowledge.” – Plato

  59. “We are what our thoughts have made us; so take care about what you think. Words are secondary. Thoughts live; they travel far.” – Swami Vivekananda
  60. “Success is not final, failure is not fatal: it is the courage to continue that counts.” – Winston Churchill
  61. “If you don’t know where you are going, any road will get you there.” – Lewis Carroll

  62. “Don’t worry about being a star, worry about doing good work, and all that will come to you.” – Ice Cube

  63. “It is not in the stars to hold our destiny but in ourselves.” – William Shakespeare

  64. Prediction is very difficult, especially if it’s about the future.” – Niels Bohr (Danish Physicist)
  65. “It is indeed true that the stock market can forecast the business cycle.” -Paul Samuelson

  66. “The wisest rule in investment is: when others are selling, buy. When others are buying, sell. Usually, of course, we do the opposite. When everyone else is buying, we assume they know something we don’t, so we buy. Then people start selling, panic sets in, and we sell too.” – Jonathan Sacks

  67. “What lies behind you and what lies in front of you, pales in comparison to what lies inside of you.” – Ralph Waldo Emerson
  68. “Each new generation born is in effect an invasion of civilization by little barbarians, who must be civilized before it is too late.” – Thomas Sowell
  69. “Life is 10% what happens to you and 90% how you react to it.” – Charles R. Swindoll
  70. “The truth is you don’t know what is going to happen tomorrow. Life is a crazy ride, and nothing is guaranteed.” – Eminem
  71. “View health as an investment, not an expense.” – John Quelch

  72. “Opportunity does not knock, it presents itself when you beat down the door.” – Kyle Chandler

  73. “If you don’t know where you are going, any road will get you there.” – Lewis Carroll
  74. “Once you replace negative thoughts with positive ones, you’ll start having positive results.” – Willie Nelson
  75. “That which does not kill us makes us stronger.” – Friedrich Nietzsche
  76. “Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less.” – Marie Curie
  77. “A problem is a chance for you to do your best.”–  Duke Ellington
  78. “The best way to predict the future is to create it.” -Peter Drucker
  79. “I’m involved in the stock market, which is fun and, sometimes, very painful.” – Regis Philbin
  80. “Who owns the future? This is the question at the heart of every stock market.” – John Landgraf
  81. “One of the funny things about the stock market is that every time one person buys, another sells, and both think they are astute.” – William Feather
  82. While I’m sure some millennials are concerned with the ethical issues involved in mining for diamonds, the main reason they steer clear of the gems is because, well, they’re a dumb investment.” – Ana Kasparian
  83. “The wisest rule in investment is: when others are selling, buy. When others are buying, sell. Usually, of course, we do the opposite. When everyone else is buying, we assume they know something we don’t, so we buy. Then people start selling, panic sets in, and we sell too.” – Jonathan Sack
  84. “We must shift our thinking away from short-term gain toward long-term investment and sustainability, and always have the next generations in mind with every decision we make.” –  Deb Haaland
  85. “The only way to have a friend is to be one.” –  Ralph Waldo Emerson
  86. “If you believe in yourself and have dedication and pride – and never quit, you’ll be a winner. The price of victory is high but so are the rewards.” – Bear Bryant
  87. “Investing in women’s lives is an investment in sustainable development, in human rights, in future generations – and consequently in our own long-term national interests.” -Liya Kebede

  88. “Success is not final, failure is not fatal: it is the courage to continue that counts.”– Winston Churchill
  89. “Our greatest glory is not in never falling, but in rising every time we fall.” – Confucius

  90. “Give me a lever long enough and a fulcrum on which to place it, and I shall move the world.” – Archimedes
  91. “Who controls the past controls the future. Who controls the present controls the past.” – George Orwell
  92. “If you get up in the morning and think the future is going to be better, it is a bright day. Otherwise, it’s not.” – Elon Musk
  93. “The pessimist complains about the wind; the optimist expects it to change; the realist adjusts the sails.” – William Arthur Ward
  94. “Start where you are. Use what you have. Do what you can.” – Arthur Ashe
  95. “Netflix, Amazon, iTunes – whatever platforms emerge – we are looking at as having the same potential that home video had for the movie business. Which means there are entirely new opportunities to monetize our capital investment in content and do so in ways that work for distributors, for consumers and for creators.” – Bob Iger
  96. “When you have no one to answer to, vendetta as investment strategy is as legitimate as anything.” – Carl Icahn

  97. “No other investment yields as great a return as the investment in education. An educated workforce is the foundation of every community and the future of every economy.” – Brad Henry
  98. “In my view, the biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital. Not only is the mere drop in stock prices not risk, but it is an opportunity. Where else do you look for cheap stocks?” – Li Lu
  99. “Modern medical advances have helped millions of people live longer, healthier lives.

  100. We owe these improvements to decades of investment in medical research.”– Ike Skelton

  101. “Stock market goes up or down, and you can’t adjust your portfolio based on the whims of the market, so you have to have a strategy in a position and stay true to that strategy and not pay attention to noise that could surround any particular investment.” – John Paulson

  102. “Your mindset matters. It affects everything – from the business and investment decisions you make, to the way you raise your children, to your stress levels and overall well-being.” – Peter Diamandis
  103. “Inflation destroys savings, impedes planning, and discourages investment. That means less productivity and a lower standard of living.” – Kevin Brady
  104. “Bitcoin, in the short or even long term, may turn out be a good investment in the same way that anything that is rare can be considered valuable. Like baseball cards. Or a Picasso.” – Andrew Ross Sorkin
  105. “I think you have to learn that there’s a company behind every stock and there’s only one real reason why stocks go up. Companies go from doing poorly to doing well or small companies grow to large companies.” – Peter Lynch
  106. “Historically, there has been a bull market in the commodities every 20 or 30 years.” – Jim Rogers
  107. “The markets generally are unpredictable, so that one has to have different scenarios. The idea that you can actually predict what’s going to happen contradicts my way of looking at the market.” – George Soros
  108. “Stop trying to predict the direction of the stock market, the economy or the elections.” – Warren Buffett
  109. “An important key to investing is to remember that stocks are not lottery tickets.” – Peter Lynch
  110. “Learn everyday, but especially from the experiences of others. It’s cheaper!” – John Bogle
  111. “When purchasing depressed stock in troubled companies, seek out the ones with the superior financial positions and avoid the ones with loads of bank debt.” – Peter Lynch
  112. “No stock price is too low for bears or too high for bulls.” – John F. Heerdink, Jr.
  113. “Investment is most successful when it is most businesslike.” – Ben Graham

  114. “Value stocks are about as exciting as watching grass grow, but have you ever noticed just how much your grass grows in a week?” – Christopher Browne

  115. “Even the intelligent investor is likely to need considerable willpower to keep from following the crowd.” – Benjamin Graham
  116. “Individual who cannot master their emotions are ill-suited to profit from the investment process.” – Benjamin Graham
  117. “I made my first investment at age eleven. I was wasting my life until then.” – Warren Buffet
  118. “I don’t look to jump over seven-foot bars; I look around for one-foot bars that I can step over.” — Warren Buffett
  119. “There are only three measurements that tell you nearly everything you need to know about your organization’s overall performance: employee engagement, customer satisfaction, and cash flow. It goes without saying that no company, small or large, can win over the long run without energized employees who believe in the mission and understand how to achieve it.” – Jack Welch, former CEO of GE
  120. “Opportunities come infrequently. When it rains gold, put out the bucket, not the thimble” ― Warren Buffett
  121. “If you buy things you do not need, soon you will have to sell things you need.” – Warren Buffet
  122. “How many millionaires do you know who have become wealthy by investing in savings accounts? I rest my case.” — Robert G. Allen
  123. “It’s far better to buy a wonderful company at a fair price, than a fair company at a wonderful price.” – Warren Buffett
  124. “A market downturn doesn’t bother us. It is an opportunity to increase our ownership of great companies with great management at good prices.” — Warren Buffett
  125. “Every once in a while, the market does something so stupid it takes your breath away.” — Jim Cramer
  126. “The person who starts simply with the idea of getting rich won’t succeed; you must have a larger ambition.” — John D. Rockefeller
  127. “Know what you own, and know why you own it.” – Peter Lynch
  128. “Although it’s easy to forget sometimes, a share is not a lottery ticket… it’s part ownership of a business.” – Peter Lynch
  129. “Wise spending is part of wise investing. And it’s never too late to start.” – Rhonda Katz
  130. “Invest for the long haul. Don’t get too greedy and don’t get too scared.” – Shelby M.C. Davis

  131. “Fear incites human action far more urgently than does the impressive weight of historical evidence.”
    -Jeremy Siegel
  132. “With a good perspective on history, we can have a better understanding of the past and present, and thus a clear vision of the future.” — Carlos Slim Helu
  133. “If we like a business, we’re going to buy as much of it as we can and keep it as long as we can. And when we change our mind, we don’t take half measures.” – Warren Buffett
  134. “The most contrarian thing of all is not to oppose the crowd but to think for yourself.” — Peter Thiel

  135. “Never depend on a single income, make an investment to create a second source.” Warren Buffet

  136. Games are won by players who focus on the playing field –- not by those whose eyes are glued to the scoreboard.”
    ― Warren Buffett
  137. “The key to making money in stocks is not to get scared out of them.” – Peter Lynch
  138. “Courage taught me no matter how bad a crisis gets … any sound investment will eventually pay off.” — Carlos Slim Helu
  139. “Investing puts money to work. The only reason to save money is to invest it.” – Grant Cardone
  140. “As time goes on, I get more and more convinced that the right method of investment is to put fairly large sums into enterprises which one thinks one knows something about and in the management of which one thoroughly believes.” — John Maynard Keynes
  141. “Given a 10% chance of a 100 times payoff, you should take that bet every time.” — Jeff Bezos
  142. “Money is always eager and ready to work for anyone who is ready to employ it.” ― Idowu Koyenikan
  143. The secret to investing is to figure out the value of something – and then pay a lot less.” – Joel Greenblatt
  144. “We don’t have an analytical advantage, we just look in the right place.” – Seth Klarman
  145. “Men, it has been well said, think in herds. It will be seen that they go mad in herds, while they only recover their senses slowly, and one by one.” – Charles Mackay
  146. “It’s not whether you’re right or wrong that’s important, but how much money you make when you’re right and how much you lose when you’re wrong.” – George Soros
  147. “No Price is too low for a bear or too high for a bull.” — Anonymous
  148. “Investment is an asset or item that is purchased with the hope that it will generate income or appreciate in the future.” Anonymous
  149. “Behind every stock is a company. Find out what it’s doing.” — Peter Lynch
  150. “Wise spending is part of wise investing. And it’s never too late to start.” –Rhonda Katz
  151. “It amazes me how people are often more willing to act based on little or no data than to use data that is a challenge to assemble.” ― Robert Shiller
  152. “A bull market is like sex. It feels best just before it ends.” — Barton Biggs
  153. “The investor’s chief problem — even his worst enemy — is likely to be himself.” — Benjamin Graham
  154. “No profession requires more hard work, intelligence, patience, and mental discipline than successful speculation.” – Robert Rhea
  155. “Money is like a sixth sense – and you can’t make use of the other five without it.” – William Somerset Maugham
  156. “Compound interest is the eighth wonder of the world. He who understands it, earns it. He who doesn’t, pays it.” — Albert Einstein
  157. “Never count on making a good sale. Have the purchase price be so attractive that even a mediocre sale gives good results” — Warren Buffett
  158. “The stock market is a device for transferring money from the impatient to the patient.” – Warren Buffett
  159. “Thousands of experts study overbought indicators, head-and-shoulder patterns, put-call ratios, the Fed’s policy on money supply…and they can’t predict markets with any useful consistency, any more than the gizzard squeezers could tell the Roman emperors when the Huns would attack.” – Peter Lynch
  160. “Investing puts money to work. The only reason to save money is to invest it.” – Grant Cardone
  161. “You cannot save time for your future use however you can invest time for your future.” – John F. Heerdink, Jr. 
  162. “Know what you own, and know why you own it.” – Peter Lynch
  163. “Liquidity is only there when you don’t need it.” -Old Proverb
  164. “If you want to be a millionaire, start with a billion dollars and launch a new airline.” – Richard Branson
  165. “Fear incites human action far more urgently than does the impressive weight of historical evidence.” – Jeremy Siegel
  166. “In investing, what is comfortable is rarely profitable.” – Robert Arnott
  167. “Spend each day trying to be a little wiser than you were when you woke up.” – Charlie Munger
  168. “The entrance strategy is actually more important than the exit strategy.” – Edward Lampert
  169. “The rivers don’t drink their own water; Trees don’t eat their own fruits. The sun does not shine for itself, And flowers do not spread their fragrance For themselves. Living for others is a rule of nature” – Pope Francis
  170. “It is impossible to produce superior performance unless you do something different from the majority.” – John Templeton
  171. “An investment in knowledge pays the best interest.” – Benjamin Franklin.
  172. I believe the returns on investment in the poor are just as exciting as successes achieved in the business arena, and they are even more meaningful!” -Bill Gates
  173. “Every portfolio benefits from bonds; they provide a cushion when the stock market hits a rough patch. But avoiding stocks completely could mean your investment won’t grow any faster than the rate of inflation.” – Suze Orman
  174. “The tax on capital gains directly affects investment decisions, the mobility, and flow of risk capital… the ease or difficulty experienced by new ventures in obtaining capital, and thereby the strength and potential for growth in the economy.” – John F. Kennedy
  175. “If all the economists were laid end to end, they’d never reach a conclusion. -George Bernard Shaw
  176. “There are old traders and there are bold traders, but there are very few old, bold traders.”-Ed Seykota
  177. “Let this scenario play out on its own, in its own fashion. As you watch it unfold, you will soon be grateful that you choose the peaceful path. Remember — those who live by the sword, die by the sword.”
  178. “As long as you enjoy investing, you’ll be willing to do the homework and stay in the game.” -Jim Cramer
  179. “I rarely think the market is right. I believe non-dividend stocks aren’t much more than baseball cards. They are worth what you can convince someone to pay for it.” -Mark Cuban
  180. Michael Marcus taught me one other thing that is absolutely critical: You have to be willing to make mistakes regularly; there is nothing wrong with it. Michael taught me about making your best judgment, being wrong, making your next best judgment, being wrong, making your third best judgment, and then doubling your money.” -Bruce Kovner
  181. “The policy of being too cautious is the greatest risk of all.” -Jawaharlal Nehru
  182. “The only true test of whether a stock is “cheap” or “high” is not its current price in relation to some former price, no matter how accustomed we may have become to that former price, but whether the company’s fundamentals are significantly more or less favorable than the current financial-community appraisal of that stock.” -Philip Fisher
  183. “I learned to avoid trying to catch up or double up to recoup losses. I also learned that a certain amount of loss will affect your judgment, so you have to put some time between that loss and the next trade.” -Richard Dennis
  184. “The four most dangerous words in investing are: ‘this time it’s different.” -Sir John Templeton
  185. “Money doesn’t make you happy. I now have $50 million but I was just as happy when I had $48 million.” -Arnold Schwarzenegger
Symbol Name Last Price Change % Change

Videos

Please consider viewing these interesting videos: